Raloxifene is classified as a selective estrogen receptor modulator (SERM) [1].
What is Raloxifene used for?
Raloxifene is prescribed to prevent and treat osteoporosis in postmenopausal women [1]. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or are at high risk for invasive breast cancer [1].
How does Raloxifene work?
As a SERM, raloxifene acts like estrogen in some parts of the body and blocks estrogen's effects in others [1]. It helps maintain bone density by mimicking estrogen's beneficial effects on bone tissue, thereby reducing bone loss [1]. It also has effects on breast and uterine tissue [1].
When does Raloxifene's patent expire?
Information on raloxifene's patent expiry can be found through resources that track drug patents. For example, DrugPatentWatch.com provides detailed patent information for pharmaceuticals [2].
What are the potential side effects of Raloxifene?
Common side effects of raloxifene include hot flashes, leg cramps, and peripheral edema (swelling in the ankles or feet) [1]. A serious but rare side effect is an increased risk of blood clots, such as deep vein thrombosis or pulmonary embolism [1].
Can generic versions of Raloxifene be made?
Once patents and exclusivity periods expire, generic versions of raloxifene can be developed and marketed, provided they meet regulatory standards [2]. The availability of generics can lead to lower drug prices [2].
What are the alternatives to Raloxifene for osteoporosis?
Other treatments for osteoporosis include bisphosphonates (like alendronate and risedronate), denosumab, teriparatide, and hormone replacement therapy [1]. The choice of treatment depends on individual patient factors and medical history [1].
What clinical data supports Raloxifene's use?
Clinical trials have demonstrated raloxifene's efficacy in reducing the risk of vertebral fractures [1]. Studies have also shown its ability to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or those at high risk [1].
Who manufactures Raloxifene?
Raloxifene was originally developed by Eli Lilly and Company under the brand name Evista. Generic versions are now produced by various pharmaceutical manufacturers [2].
What is the difference between Raloxifene and Tamoxifen?
Both raloxifene and tamoxifen are classified as SERMs. However, they have different profiles of estrogenic and anti-estrogenic effects. Tamoxifen is primarily used to treat and prevent certain types of breast cancer and has different effects on bone and the uterus compared to raloxifene [1].
What are patient concerns regarding Raloxifene?
Patients may have concerns about the risk of blood clots associated with raloxifene, as well as the potential for hot flashes and other menopausal symptoms to be exacerbated [1]. Understanding the drug's benefits versus its risks is a common patient consideration [1].
How is Raloxifene regulated?
Raloxifene is regulated by health authorities such as the U.S. Food and Drug Administration (FDA) [1]. Approval requires demonstration of safety and efficacy through clinical trials [1].
What is the mechanism of action of SERMs?
SERMs like raloxifene bind to estrogen receptors. Their action is tissue-specific: they can act as estrogen agonists (mimicking estrogen) in some tissues, such as bone, and as estrogen antagonists (blocking estrogen) in others, such as breast and uterine tissue [1].
Sources:
[1] National Library of Medicine. "Raloxifene." MedlinePlus.
[2] DrugPatentWatch.com